The frequent use of corticosteroid inhalers (CSIs), especially at higher doses, has been accompanied by concern about both systemic and local adverse reactions. The local adverse reactions of inhaled corticosteroids (ICSs) are considered to constitute infrequent and minor problems. However, while not usually serious, these local adverse reactions are of clinical importance. This study assessed the prevalence of local adverse reactions, their clinical features, role of inhaler devices and current measures that have been suggested to prevent the problem.
INTRODUCTION
Asthma is a chronic inflammatory disorder of the airways characterized by recurrent episodes of wheezing, breathlessness, chest tightness, and coughing (1) . Bronchial hyperresponsiveness and variable air-flow obstruction in asthma are consequences of the activity of numerous mediators and inflammatory cells that can cause persistent airway inflammation and remodeling of the airways through fibrosis and smooth muscle cell proliferation (2, 3) .
Asthma usually begins in childhood or adolescence but can develop at any time in life (4) . The frequent use of CSIs for the treatment of persistent asthma, although highly effective, accompanies concern of both systemic and local adverse reactions (5) . Systemic adverse reactions of ICSs have been extensively studied. Comparatively, few studies have been performed to specifically evaluate local adverse reactions of ICSs. These local adverse reactions -including TANAFFOS oropharyngeal candidiasis, dysphonia, pharyngitis, tongue abrasion, choking, tongue burning and cough -are generally considered to constitute infrequent and minor problems (4, (6) (7) (8) . However, they can be clinically significant, affect patients' quality of life, may hamper compliance with therapy, and mask symptoms of more serious disease. Local adverse reactions result from deposition of actively ICSs in the oropharynx during administration of the drug (9) . Numerous factors can influence the proportion of an inhaled dose that is deposited in the oropharyngeal cavity, including the ICS formulation, type of delivery system, and patient's compliance with administration instructions. Therefore, the incidence of local adverse reactions can vary widely (4, It is speculated that inflammation is a result of irritation of oropharyngeal mucosa caused by residue from the inhaled substance (7, 11 
MATERIALS AND METHODS
This study was performed at the YAS clinic in Tabriz inhaled doses of corticosteroids were also considered, low doses were defined as less than or equal to 500 µg/day and high doses were defined as more than 500 µg/day ICSs. Frequency of the usage of CSIs compared to oral prednisolone is described in Figure 1 . Maximum and minimum frequency of using ICSs was 61.6% (n=308) for seretide and 2.6% (n=13) for Beclomethasone, respectively.
In general, occurrences of the complications were as described in Figure 2 . The prevalence of these complications was different from 8.8% (n=44) laryngeal weakness to 36.2% (n=181) speechlessness. showed that not using spacers is one of the risk factors for precipitation of drug and its related local adverse effects.
The difference between effects of using and not using spacers on the numbers of local adverse reactions is shown in Figure 3 . The patients who did not use spacers showed significantly more adverse reactions compared to those who did (P<0.001). The prevalence of different local adverse reactions in the patients who were using and not using spacers is shown in Figure 4 . All local adverse reactions were significantly greater in patients who did not use spacers compared to those who did (P<0.001). The effect of mouth wash on the removal of drug residues from both mouth and pharynx after the use of CSIs was also reported (16, 17); 52.4% of our patients used mouth wash after ICSs, and the results showed that not using mouth wash affected local adverse reactions (P<0.01). The prevalence of different local adverse reactions in the patients who were using mouth washes and those not washing their mouths after using CSIs is shown in Figure 5 . All local adverse reactions were significantly greater in those who washed their mouths after using CSIs compared to those who did not (P<0.001) ( Figure 6 ). to minimize laryngeal and pharyngeal deposition of the inhaled material. In one study, this has been shown to be of some benefits (8) . However, in contrast, another study found that cough was a spacer device-dependent side effect (6) . Previous treatment with other ICSs and devices resulting in local adverse reactions may lead to carry-over effects.
Our study showed that more than 60% of the asthmatic patients treated with CSIs were affected by at least one local side effect in daily life. This high incidence of ICSinduced adverse reactions in patients was in contrast to the results of a recent questionnaire survey which estimated that only 3% of adults and adolescents developed frequent local oropharyngeal side-effects (18) . This unexpected gap between both reports may be due to our clinical population with moderate to severe asthma requiring relatively high doses of ICSs. Oral candidiasis has been widely studied in ICS therapy and has an incidence of 0-77% due to differences in diagnostic criteria (19) (20) (21) (22) (23) . This side effect may be due to a decreased local immunity or to an increase in salivary glucose, which stimulates Candida albicans' growth (22, 23) . In our study, where clinical criteria were used, oral candidiasis was observed in 25.6% of the patients. However, the frequency of candidiasis may be underestimated, as Shaw and Edmunds (21) and not by laryngeal candidiasis (22, 24) . Indeed, Toogood et al. (19) showed that BDP, but not chlorofluorocarbon or excipients, induced dysphonia. In a similar manner, dysphonia was reported with the budesonide (BUD)
turbuhaler, which contains no excipients or propellant (8, (25) (26) (27) . Finally, dysphonia ceased when CSI use was stopped (8, 26) . As in adults (8, (25) (26) (27) , dysphonia was more frequently observed in children using a spacer 
